摘要血液肿瘤起源于造血系统，包括白血病、淋巴瘤和多发性骨髓瘤(MM)等，其病因和发病机制均尚未完全明确，部分患者预后差。程序性细胞死亡(PCD)指机体为维持内环境稳态，由基因调控的细胞自主有序死亡，根据细胞死亡机制不同，可分为凋亡、自噬、坏死性凋亡、细胞焦亡、铁死亡等。PCD相关基因的异常表达可影响血液肿瘤细胞增殖，而通过激活或者抑制PCD相关基因可干预血液肿瘤的进展。笔者拟就PCD相关基因在血液肿瘤中的研究现状进行阐述，旨在探索血液肿瘤发生、发展的分子机制，为血液肿瘤患者的预后精准预测及分子靶向治疗提供参考依据。

abstractsHematologic neoplasms originate from hematopoietic system, including leukemia, lymphoma, multiple myeloma (MM) and so on. Etiology and pathogenesis of hematologic neoplasms have not been completely clarified, and some patients have poor prognosis. Programmed cell death (PCD) refers to autonomous and orderly death of cells controlled by genes to maintain stability of internal environment. According to different mechanisms of cell death, PCD can be divided into apoptosis, autophagy, necroptosis, pyroptosis, ferroptosis and so on. Abnormal expression of PCD-related genes can affect cell proliferation of hematologic neoplasms, and progression of hematologic neoplasms can be interfered by activating or inhibiting PCD-related genes. This article aims to expound research status of PCD-related genes in hematological neoplasms, so as to provide a reference for molecular mechanisms of hematological neoplasms occurrence and development, accurate prognosis prediction and molecular targeted therapy of hematologic neoplasms.